Delivery Order SPE2DB22D1106-SPE2DB24FEYB9

Award Date 6/20/24
Potential Completion Date 6/21/24
Potential Value $75K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,572.92 firm fixed price delivery order is for the supply of 4 mg Ondansetron HCL tablets. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical division. This IDC serves as a primary vehicle for providing a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $25,105.16 firm-fixed-price delivery order is for the supply of 500 units of 4 mg Ondansetron HCL tablets. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive...
This federal contract award is an order placed by the Defense Logistics Agency (DLA) with AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4 mg Ondansetron HCL tablets. The Firm Fixed Price contract, valued at $12,075.24, has a period of performance through January 29, 2025. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,828.36 firm fixed-price delivery order is for the supply of 4 mg Ondansetron HCl tablets. The contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,351.53 Firm Fixed Price Delivery Order is for the supply of 30-count packs of 4 mg Ondansetron HCL tablets, with a period of performance through December 23, 2024. The contract is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,914.83 delivery order contract is for the supply of 4,566,188,517 units of 8 mg Ondansetron HCL tablets, with a period of performance ending on October 24, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $62,997.07 Firm Fixed Price Delivery Order is for the supply of 4 mg Ondansetron HCL tablets in quantities of 500's. The contract has an ultimate completion date of April 21, 2023. This award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the...
This federal contract award, issued by the Defense Logistics Agency (DLA), was granted to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,685.69 firm fixed-price delivery order is for the supply of 4 mg Ondansetron HCL tablets. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,098.88 firm fixed-price delivery order is for the supply of Ondansetron ODT 8 mg tablets. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,790.90 firm fixed-price delivery order is for the supply of 4 mg Ondansetron Orally Disintegrating Tablets to support federal healthcare programs. The contract is not designated with a set-aside requirement, indicating open competition. It is associated with a larger Indefinite Delivery Contract (IDC) held by...
  • SPE2DB22D1106
    Indefinite Delivery Contract
  • SPE2DB22D1106-SPE2DB24FEYB9
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $75,440.91 firm fixed-price delivery order is for the supply of 500 packs of 8 mg Ondansetron HCl tablets. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which covers a comprehensive range of pharmaceutical products and medical supplies for military healthcare programs. There is no set-aside designation indicated for this award. The contract has a performance period through June 2024.

Generated 5/17/25, 9:49 AM